Helix BioPharma Corp. Establishes Polish Subsidiary
28 August 2013 - 4:15PM
Marketwired
Helix BioPharma Corp. ("Helix") (TSX: HBP) (FRANKFURT: HBP), a
biopharmaceutical company developing drug candidates for the
prevention and treatment of cancer, today announced that it has
established a Polish subsidiary ("
Helix
Polska"). Helix Polska was established to facilitate and
support ongoing clinical oncology research at leading research
institutions in Poland.
"Establishing Helix Polska further strengthens Canadian-Polish
relationships and scientific collaboration, which commenced in 2005
when Polish investors first became shareholders of Helix", said
Robert Verhagen, Chief Executive Officer of Helix. "We recognize
that our relationship with the various leading Polish institutions
is important to our success, and Helix Polska will allow us to more
effectively communicate and interact with these groups".
Helix is actively developing innovative products for the
treatment and prevention of cancer based on its proprietary
technologies. Helix's product development initiatives are focused
primarily on its novel L-DOS47 and Topical Interferon Alpha-2b new
drug candidates.
Helix is currently conducting a European Phase I/II clinical
study in Poland with L-DOS47 in patients with inoperable, locally
advanced, recurrent or metastatic, non-squamous stage non-small
cell lung cancer ("NSCLC"). The study is being conducted at four
Polish centers, with oversight from Helix's European medical
director, Prof. Kazimierz Roszkowski-Śliża, PhD and under the
direction of Prof. Maciej Krzakowski, MD, PhD at The Maria
Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology
as the overall coordinating investigator, together with three other
principal investigators: Prof. Cezary Szczylik, MD, PhD at the
Military Medical Institute, Prof. Elzbieta Wiatr, MD, PhD at the
National Tuberculosis and Lung Diseases Research Institute and Dr.
Aleksandra Szczensa, MD, PhD at the Mazovian Center of Pulmonary
Diseases and Tuberculosis in Otwock.
Topical Interferon Alpha-2b is a developmental product candidate
for the treatment of certain skin/mucosal lesions caused by human
papilloma virus ("HPV"), based on the Company's proprietary
Biphasix™ technology. To date, the Company has completed three
Phase II clinical studies with Topical Interferon Alpha-2b; two in
patients with HPV-positive, low-grade cervical dysplasia and one in
patients with HPV-positive ano-genital warts. Of these two
therapeutic indications, efficacy was demonstrated only against
low-grade cervical dysplasia, for which the Company obtained
regulatory approvals to conduct more advanced, pivotal efficacy
trials. Helix has now limited ongoing activities of its Topical
Interferon Alpha-2b program to sourcing and qualifying alternative
interferon alpha-2b raw material samples, and finding suitable
strategic partner(s) who would be willing to license or acquire the
product and support the remaining development costs through to
commercial launch.
This release is being issued to correct
information which appeared in a press release issued by Point of
View S.p. Z.o.o on August 27, 2013.
Forward-Looking Statements and Risks and
Uncertainties This news release contains certain
forward-looking statements and information (collectively,
"forward-looking statements") within the meaning of applicable
Canadian securities laws. Forward-looking statements, which may be
identified by words including, without limitation, "will" and other
similar expressions, are intended to provide information about
management's current plans and expectations regarding future
operations.
Although Helix believes that the expectations reflected in such
forward-looking statements are reasonable, such statements involve
risks and uncertainties that may cause actual results or events to
differ materially from those anticipated and no assurance can be
given that these expectations will be realized, and undue reliance
should not be placed on such statements. Risk factors that could
cause actual results or events to differ materially from the
forward-looking statements include, without limitation, those
described in Helix's Annual Information Form, including under the
headings "Forward-Looking Statements" and "Risk Factors", filed
with the Canadian Securities Administrators at www.sedar.com
(together, the "Helix Risk Factors"). Certain material factors or
assumptions are applied in making the forward-looking statements,
including, without limitation, the Helix Risk Factors will not
cause Helix's actual results or events to differ materially from
the forward-looking statements.
Forward-looking statements and information are based on the
beliefs, assumptions and expectations of Helix's management on the
date of this news release, and Helix does not assume any obligation
to update any forward-looking statement or information should those
beliefs, assumptions or expectations, or other circumstances
change, except as required by law.
Investor Relations: Helix BioPharma Corp. Tel: 905
841-2300 Email: ir@helixbiopharma.com
Helix BioPharma (TSX:HBP)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Helix BioPharma (TSX:HBP)
Historical Stock Chart
Von Mai 2023 bis Mai 2024